"Diabetes technology is evolving in a very exciting way," said Jeff Dachis, CEO and Founder of One Drop. "But not surprisingly for the vast majority of people with diabetes worldwide, expensive sensors, automated insulin delivery solutions, or call center approaches to care can create barriers and challenges to effective disease management.” This statement came from a MannKind (NASDAQ: MNKD) press release announcing a new clinical trial.
Per that same release;
“Appropriate people with type 2 diabetes who meet inclusion criteria will be randomized to one of two treatment arms: Afrezza® with One Drop | Premium — or — One Drop | Premium alone. Changes . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.